Tuesday, October 4, 2022


Biotechnology News Magazine

Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual Meeting

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

April 9, 2021

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines.

Today they announced that a late-breaking abstract featuring new data in patients with hidradenitis suppurativa (HS) from its non-interventional study of patients with HS or atopic dermatitis (AD) has been selected for presentation at the Society for Investigative Dermatology (SID) 2021 Annual Meeting, being held virtually May 3-8, 2021.

The non-interventional study is evaluating expression of IRAK4 and other mediators of inflammation in the skin and blood of patients with HS or AD and the ex vivo effect of the IRAK4 degrader KT-474.

Abstract Presentation Details:

  • Abstract: LB819
  • Title: Multiple mediators of inflammation correlate with IRAK4 expression in the skin of hidradenitis suppurativa patients and are blocked by the IRAK4 protein degrader KT-474 in TLR-activated monocytes
  • Session: Translational Studies
  • Session Time: 2:30 PM-4:00 PM ET on Thursday, May 6th, 2021
  • Presenter: Afsaneh Alavi, MD, Mayo Clinic (Principal Investigator)

The presentation will be available on-demand from May 3-31, 2021, and also will be available for download here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine